Category Archive: Cell and Gene Therapy (CGT)

Nov 23

Considerations for Early-Phase Clinical Trial Design for Cell and Gene Therapy Products

Considerations for Early-Phase Clinical Trial Design for Cell and Gene Therapy Products By Michelle Villasmil, Ph.D., Scientist at Cato Research Despite the potential benefits of cell and gene therapy (CGT), early experiences with some CGT products have presented considerable risks to patients. These risks include possible prolonged biological activity after administration, a high likelihood for …

Continue reading »